The phase 3 FLAURA trial demonstrated that patients with previously untreated advanced NSCLC with an EGFR mutation had longer overall survival when treated with osimertinib monotherapy compared to those receiving other EGFR‐TKIs (38.6 vs. 31.8 months, respectively). Here, EGFR is linked to non-small cell lung carcinoma.